APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Screening Software

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Lung Cancer Screening Software Market Analysis and Forecast 2026-2032

Report ID 174180190222 January 2026191 pages

Choose your research edition.

Industry ResearchLung Cancer Screening Software Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Screening Software Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Lung Cancer Screening Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Screening Software Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Screening Software Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Lung Cancer Screening Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Lung Cancer Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Lung Cancer Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Lung Cancer Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Lung Cancer Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Lung Cancer Screening Software include Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, United Imaging Healthcare, InferVision, Airdoc, VUNO and Lunit, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Lung Cancer Screening Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Lung Cancer Screening Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Lung Cancer Screening Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Lung Cancer Screening Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Lung Cancer Screening Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Lung Cancer Screening Software revenue, projected growth trends, production technology, application and end-user industry.

Lung Cancer Screening Software Segment by Company

Siemens Healthineers

GE HealthCare

Philips Healthcare

Canon Medical Systems

United Imaging Healthcare

InferVision

Airdoc

VUNO

Lunit

Qure.ai

Riverain Technologies

Zebra Medical Vision

Arterys

Deepwise

EverFortune AI

Lung Cancer Screening Software Segment by Type

Cloud-Based

Web-Based

Lung Cancer Screening Software Segment by Application

Hospitals

Medical Examination Institutions

Public Health Screening

Others

Lung Cancer Screening Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Screening Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Screening Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Screening Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Lung Cancer Screening Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Lung Cancer Screening Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lung Cancer Screening Software revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Lung Cancer Screening Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cloud-Based Major Player Table 3. Web-Based Major Player Table 4. Global Lung Cancer Screening Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Player Table 6. Medical Examination Institutions Major Player Table 7. Public Health Screening Major Player Table 8. Others Major Player Table 9. Lung Cancer Screening Software Industry Trends Table 10. Lung Cancer Screening Software Industry Drivers Table 11. Lung Cancer Screening Software Industry Opportunities and Challenges Table 12. Lung Cancer Screening Software Industry Restraints Table 13. Global Lung Cancer Screening Software Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Lung Cancer Screening Software Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Lung Cancer Screening Software Market Share by Region (2021-2026) Table 16. Global Lung Cancer Screening Software Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Lung Cancer Screening Software Market Share by Region (2027-2032) Table 18. Global Lung Cancer Screening Software Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Lung Cancer Screening Software Revenue Market Share by Players (2021-2026) Table 20. Global Lung Cancer Screening Software Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Lung Cancer Screening Software Key Players Headquarters & Area Served Table 22. Global Lung Cancer Screening Software Players, Product Type & Application Table 23. Global Lung Cancer Screening Software Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Lung Cancer Screening Software by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Lung Cancer Screening Software Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Lung Cancer Screening Software Revenue Market Share by Type (2021-2026) Table 30. Global Lung Cancer Screening Software Revenue Market Share by Type (2027-2032) Table 31. Global Lung Cancer Screening Software Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Lung Cancer Screening Software Revenue Market Share by Application (2021-2026) Table 35. Global Lung Cancer Screening Software Revenue Market Share by Application (2027-2032) Table 36. Siemens Healthineers Company Information Table 37. Siemens Healthineers Business Overview Table 38. Siemens Healthineers Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Siemens Healthineers Lung Cancer Screening Software Product Portfolio Table 40. Siemens Healthineers Recent Development Table 41. GE HealthCare Company Information Table 42. GE HealthCare Business Overview Table 43. GE HealthCare Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. GE HealthCare Lung Cancer Screening Software Product Portfolio Table 45. GE HealthCare Recent Development Table 46. Philips Healthcare Company Information Table 47. Philips Healthcare Business Overview Table 48. Philips Healthcare Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Philips Healthcare Lung Cancer Screening Software Product Portfolio Table 50. Philips Healthcare Recent Development Table 51. Canon Medical Systems Company Information Table 52. Canon Medical Systems Business Overview Table 53. Canon Medical Systems Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Canon Medical Systems Lung Cancer Screening Software Product Portfolio Table 55. Canon Medical Systems Recent Development Table 56. United Imaging Healthcare Company Information Table 57. United Imaging Healthcare Business Overview Table 58. United Imaging Healthcare Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. United Imaging Healthcare Lung Cancer Screening Software Product Portfolio Table 60. United Imaging Healthcare Recent Development Table 61. InferVision Company Information Table 62. InferVision Business Overview Table 63. InferVision Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. InferVision Lung Cancer Screening Software Product Portfolio Table 65. InferVision Recent Development Table 66. Airdoc Company Information Table 67. Airdoc Business Overview Table 68. Airdoc Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Airdoc Lung Cancer Screening Software Product Portfolio Table 70. Airdoc Recent Development Table 71. VUNO Company Information Table 72. VUNO Business Overview Table 73. VUNO Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. VUNO Lung Cancer Screening Software Product Portfolio Table 75. VUNO Recent Development Table 76. Lunit Company Information Table 77. Lunit Business Overview Table 78. Lunit Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Lunit Lung Cancer Screening Software Product Portfolio Table 80. Lunit Recent Development Table 81. Qure.ai Company Information Table 82. Qure.ai Business Overview Table 83. Qure.ai Lung Cancer Screening Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Qure.ai Lung Cancer Screening Software Product Portfolio Table 85. Qure.ai Recent Development Table 86. Riverain Technologies Company Information Table 87. Riverain Technologies Business Overview Table 88. Riverain Technologies Lung Cancer Screening Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Riverain Technologies Lung Cancer Screening Software Product Portfolio Table 90. Riverain Technologies Recent Development Table 91. Zebra Medical Vision Company Information Table 92. Zebra Medical Vision Business Overview Table 93. Zebra Medical Vision Lung Cancer Screening Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Zebra Medical Vision Lung Cancer Screening Software Product Portfolio Table 95. Zebra Medical Vision Recent Development Table 96. Arterys Company Information Table 97. Arterys Business Overview Table 98. Arterys Lung Cancer Screening Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Arterys Lung Cancer Screening Software Product Portfolio Table 100. Arterys Recent Development Table 101. Deepwise Company Information Table 102. Deepwise Business Overview Table 103. Deepwise Lung Cancer Screening Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Deepwise Lung Cancer Screening Software Product Portfolio Table 105. Deepwise Recent Development Table 106. EverFortune AI Company Information Table 107. EverFortune AI Business Overview Table 108. EverFortune AI Lung Cancer Screening Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. EverFortune AI Lung Cancer Screening Software Product Portfolio Table 110. EverFortune AI Recent Development Table 111. North America Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Lung Cancer Screening Software Revenue by Country (2021-2026) & (US$ Million) Table 117. North America Lung Cancer Screening Software Revenue by Country (US$ Million) & (2027-2032) Table 118. Europe Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Lung Cancer Screening Software Revenue by Country (2021-2026) & (US$ Million) Table 124. Europe Lung Cancer Screening Software Revenue by Country (US$ Million) & (2027-2032) Table 125. China Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 126. China Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 127. China Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 128. China Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 130. Asia Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 131. Asia Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 132. Asia Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Lung Cancer Screening Software Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Lung Cancer Screening Software Revenue by Region (US$ Million) & (2021-2026) Table 135. Asia Lung Cancer Screening Software Revenue by Region (US$ Million) & (2027-2032) Table 136. SAMEA Lung Cancer Screening Software Revenue by Type (2021-2026) & (US$ Million) Table 137. SAMEA Lung Cancer Screening Software Revenue by Type (2027-2032) & (US$ Million) Table 138. SAMEA Lung Cancer Screening Software Revenue by Application (2021-2026) & (US$ Million) Table 139. SAMEA Lung Cancer Screening Software Revenue by Application (2027-2032) & (US$ Million) Table 140. SAMEA Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. SAMEA Lung Cancer Screening Software Revenue by Country (2021-2026) & (US$ Million) Table 142. SAMEA Lung Cancer Screening Software Revenue by Country (US$ Million) & (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Lung Cancer Screening Software Image Figure 2. Global Lung Cancer Screening Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Screening Software Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cloud-Based Image Figure 5. Web-Based Image Figure 6. Global Lung Cancer Screening Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Lung Cancer Screening Software Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Medical Examination Institutions Image Figure 10. Public Health Screening Image Figure 11. Others Image Figure 12. Global Lung Cancer Screening Software Market Size (US$ Million) & (2021-2032) Figure 13. Global Lung Cancer Screening Software Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Lung Cancer Screening Software Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Lung Cancer Screening Software Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Lung Cancer Screening Software Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Lung Cancer Screening Software Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Lung Cancer Screening Software Revenue Market Share by Type (2021-2032) Figure 20. Global Lung Cancer Screening Software Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Lung Cancer Screening Software Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Lung Cancer Screening Software Revenue Market Share by Application (2021-2032) Figure 23. North America Lung Cancer Screening Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Lung Cancer Screening Software Revenue Share by Type (2021-2032) Figure 25. North America Lung Cancer Screening Software Revenue Share by Application (2021-2032) Figure 26. North America Lung Cancer Screening Software Revenue Share by Country (2021-2032) Figure 27. United States Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Lung Cancer Screening Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Lung Cancer Screening Software Revenue Share by Type (2021-2032) Figure 32. Europe Lung Cancer Screening Software Revenue Share by Application (2021-2032) Figure 33. Europe Lung Cancer Screening Software Revenue Share by Country (2021-2032) Figure 34. Germany Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Lung Cancer Screening Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Lung Cancer Screening Software Revenue Share by Type (2021-2032) Figure 44. China Lung Cancer Screening Software Revenue Share by Application (2021-2032) Figure 45. Asia Lung Cancer Screening Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Lung Cancer Screening Software Revenue Share by Type (2021-2032) Figure 47. Asia Lung Cancer Screening Software Revenue Share by Application (2021-2032) Figure 48. Asia Lung Cancer Screening Software Revenue Share by Region (2021-2032) Figure 49. Japan Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Lung Cancer Screening Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Lung Cancer Screening Software Revenue Share by Type (2021-2032) Figure 57. SAMEA Lung Cancer Screening Software Revenue Share by Application (2021-2032) Figure 58. SAMEA Lung Cancer Screening Software Revenue Share by Country (2021-2032) Figure 59. Brazil Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Lung Cancer Screening Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cloud-Based
  • Web-Based
Applications
  • Hospitals
  • Medical Examination Institutions
  • Public Health Screening
  • Others
Companies covered
  • Siemens Healthineers
  • GE HealthCare
  • Philips Healthcare
  • Canon Medical Systems
  • United Imaging Healthcare
  • InferVision
  • Airdoc
  • VUNO
  • Lunit
  • Qure.ai
  • Riverain Technologies
  • Zebra Medical Vision
  • Arterys
  • Deepwise
  • EverFortune AI

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Lung Cancer Screening Software Market by Type
  3. 1.2.1 Global Lung Cancer Screening Software Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cloud-Based
  5. 1.2.3 Web-Based
  6. 1.3 Lung Cancer Screening Software Market by Application
  7. 1.3.1 Global Lung Cancer Screening Software Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Medical Examination Institutions
  10. 1.3.4 Public Health Screening
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Lung Cancer Screening Software Market Dynamics
  1. 2.1 Lung Cancer Screening Software Industry Trends
  2. 2.2 Lung Cancer Screening Software Industry Drivers
  3. 2.3 Lung Cancer Screening Software Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Screening Software Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Lung Cancer Screening Software Market Perspective (2021-2032)
  2. 3.2 Global Lung Cancer Screening Software Growth Trends by Region
  3. 3.2.1 Global Lung Cancer Screening Software Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Lung Cancer Screening Software Market Size by Region (2021-2026)
  5. 3.2.3 Global Lung Cancer Screening Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Lung Cancer Screening Software Revenue by Players
  2. 4.1.1 Global Lung Cancer Screening Software Revenue by Players (2021-2026)
  3. 4.1.2 Global Lung Cancer Screening Software Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Lung Cancer Screening Software Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Lung Cancer Screening Software Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Lung Cancer Screening Software Key Players Headquarters & Area Served
  7. 4.4 Global Lung Cancer Screening Software Players, Product Type & Application
  8. 4.5 Global Lung Cancer Screening Software Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Lung Cancer Screening Software Market CR5 and HHI
  11. 4.6.3 2025 Lung Cancer Screening Software Tier 1, Tier 2, and Tier 3
5 Lung Cancer Screening Software Market Size by Type
  1. 5.1 Global Lung Cancer Screening Software Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 5.3 Global Lung Cancer Screening Software Revenue Market Share by Type (2021-2032)
6 Lung Cancer Screening Software Market Size by Application
  1. 6.1 Global Lung Cancer Screening Software Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Lung Cancer Screening Software Revenue by Application (2021-2032)
  3. 6.3 Global Lung Cancer Screening Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Siemens Healthineers
  2. 7.1.1 Siemens Healthineers Company Information
  3. 7.1.2 Siemens Healthineers Business Overview
  4. 7.1.3 Siemens Healthineers Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Siemens Healthineers Lung Cancer Screening Software Product Portfolio
  6. 7.1.5 Siemens Healthineers Recent Developments
  7. 7.2 GE HealthCare
  8. 7.2.1 GE HealthCare Company Information
  9. 7.2.2 GE HealthCare Business Overview
  10. 7.2.3 GE HealthCare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GE HealthCare Lung Cancer Screening Software Product Portfolio
  12. 7.2.5 GE HealthCare Recent Developments
  13. 7.3 Philips Healthcare
  14. 7.3.1 Philips Healthcare Company Information
  15. 7.3.2 Philips Healthcare Business Overview
  16. 7.3.3 Philips Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Philips Healthcare Lung Cancer Screening Software Product Portfolio
  18. 7.3.5 Philips Healthcare Recent Developments
  19. 7.4 Canon Medical Systems
  20. 7.4.1 Canon Medical Systems Company Information
  21. 7.4.2 Canon Medical Systems Business Overview
  22. 7.4.3 Canon Medical Systems Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Canon Medical Systems Lung Cancer Screening Software Product Portfolio
  24. 7.4.5 Canon Medical Systems Recent Developments
  25. 7.5 United Imaging Healthcare
  26. 7.5.1 United Imaging Healthcare Company Information
  27. 7.5.2 United Imaging Healthcare Business Overview
  28. 7.5.3 United Imaging Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  29. 7.5.4 United Imaging Healthcare Lung Cancer Screening Software Product Portfolio
  30. 7.5.5 United Imaging Healthcare Recent Developments
  31. 7.6 InferVision
  32. 7.6.1 InferVision Company Information
  33. 7.6.2 InferVision Business Overview
  34. 7.6.3 InferVision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  35. 7.6.4 InferVision Lung Cancer Screening Software Product Portfolio
  36. 7.6.5 InferVision Recent Developments
  37. 7.7 Airdoc
  38. 7.7.1 Airdoc Company Information
  39. 7.7.2 Airdoc Business Overview
  40. 7.7.3 Airdoc Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Airdoc Lung Cancer Screening Software Product Portfolio
  42. 7.7.5 Airdoc Recent Developments
  43. 7.8 VUNO
  44. 7.8.1 VUNO Company Information
  45. 7.8.2 VUNO Business Overview
  46. 7.8.3 VUNO Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  47. 7.8.4 VUNO Lung Cancer Screening Software Product Portfolio
  48. 7.8.5 VUNO Recent Developments
  49. 7.9 Lunit
  50. 7.9.1 Lunit Company Information
  51. 7.9.2 Lunit Business Overview
  52. 7.9.3 Lunit Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Lunit Lung Cancer Screening Software Product Portfolio
  54. 7.9.5 Lunit Recent Developments
  55. 7.10 Qure.ai
  56. 7.10.1 Qure.ai Company Information
  57. 7.10.2 Qure.ai Business Overview
  58. 7.10.3 Qure.ai Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Qure.ai Lung Cancer Screening Software Product Portfolio
  60. 7.10.5 Qure.ai Recent Developments
  61. 7.11 Riverain Technologies
  62. 7.11.1 Riverain Technologies Company Information
  63. 7.11.2 Riverain Technologies Business Overview
  64. 7.11.3 Riverain Technologies Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Riverain Technologies Lung Cancer Screening Software Product Portfolio
  66. 7.11.5 Riverain Technologies Recent Developments
  67. 7.12 Zebra Medical Vision
  68. 7.12.1 Zebra Medical Vision Company Information
  69. 7.12.2 Zebra Medical Vision Business Overview
  70. 7.12.3 Zebra Medical Vision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Zebra Medical Vision Lung Cancer Screening Software Product Portfolio
  72. 7.12.5 Zebra Medical Vision Recent Developments
  73. 7.13 Arterys
  74. 7.13.1 Arterys Company Information
  75. 7.13.2 Arterys Business Overview
  76. 7.13.3 Arterys Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Arterys Lung Cancer Screening Software Product Portfolio
  78. 7.13.5 Arterys Recent Developments
  79. 7.14 Deepwise
  80. 7.14.1 Deepwise Company Information
  81. 7.14.2 Deepwise Business Overview
  82. 7.14.3 Deepwise Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Deepwise Lung Cancer Screening Software Product Portfolio
  84. 7.14.5 Deepwise Recent Developments
  85. 7.15 EverFortune AI
  86. 7.15.1 EverFortune AI Company Information
  87. 7.15.2 EverFortune AI Business Overview
  88. 7.15.3 EverFortune AI Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  89. 7.15.4 EverFortune AI Lung Cancer Screening Software Product Portfolio
  90. 7.15.5 EverFortune AI Recent Developments
8 North America
  1. 8.1 North America Lung Cancer Screening Software Revenue (2021-2032)
  2. 8.2 North America Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 8.2.1 North America Lung Cancer Screening Software Revenue by Type (2021-2026)
  4. 8.2.2 North America Lung Cancer Screening Software Revenue by Type (2027-2032)
  5. 8.3 North America Lung Cancer Screening Software Revenue Share by Type (2021-2032)
  6. 8.4 North America Lung Cancer Screening Software Revenue by Application (2021-2032)
  7. 8.4.1 North America Lung Cancer Screening Software Revenue by Application (2021-2026)
  8. 8.4.2 North America Lung Cancer Screening Software Revenue by Application (2027-2032)
  9. 8.5 North America Lung Cancer Screening Software Revenue Share by Application (2021-2032)
  10. 8.6 North America Lung Cancer Screening Software Revenue by Country
  11. 8.6.1 North America Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Lung Cancer Screening Software Revenue by Country (2021-2026)
  13. 8.6.3 North America Lung Cancer Screening Software Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Lung Cancer Screening Software Revenue (2021-2032)
  2. 9.2 Europe Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 9.2.1 Europe Lung Cancer Screening Software Revenue by Type (2021-2026)
  4. 9.2.2 Europe Lung Cancer Screening Software Revenue by Type (2027-2032)
  5. 9.3 Europe Lung Cancer Screening Software Revenue Share by Type (2021-2032)
  6. 9.4 Europe Lung Cancer Screening Software Revenue by Application (2021-2032)
  7. 9.4.1 Europe Lung Cancer Screening Software Revenue by Application (2021-2026)
  8. 9.4.2 Europe Lung Cancer Screening Software Revenue by Application (2027-2032)
  9. 9.5 Europe Lung Cancer Screening Software Revenue Share by Application (2021-2032)
  10. 9.6 Europe Lung Cancer Screening Software Revenue by Country
  11. 9.6.1 Europe Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Lung Cancer Screening Software Revenue by Country (2021-2026)
  13. 9.6.3 Europe Lung Cancer Screening Software Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Lung Cancer Screening Software Revenue (2021-2032)
  2. 10.2 China Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 10.2.1 China Lung Cancer Screening Software Revenue by Type (2021-2026)
  4. 10.2.2 China Lung Cancer Screening Software Revenue by Type (2027-2032)
  5. 10.3 China Lung Cancer Screening Software Revenue Share by Type (2021-2032)
  6. 10.4 China Lung Cancer Screening Software Revenue by Application (2021-2032)
  7. 10.4.1 China Lung Cancer Screening Software Revenue by Application (2021-2026)
  8. 10.4.2 China Lung Cancer Screening Software Revenue by Application (2027-2032)
  9. 10.5 China Lung Cancer Screening Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Lung Cancer Screening Software Revenue (2021-2032)
  2. 11.2 Asia Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 11.2.1 Asia Lung Cancer Screening Software Revenue by Type (2021-2026)
  4. 11.2.2 Asia Lung Cancer Screening Software Revenue by Type (2027-2032)
  5. 11.3 Asia Lung Cancer Screening Software Revenue Share by Type (2021-2032)
  6. 11.4 Asia Lung Cancer Screening Software Revenue by Application (2021-2032)
  7. 11.4.1 Asia Lung Cancer Screening Software Revenue by Application (2021-2026)
  8. 11.4.2 Asia Lung Cancer Screening Software Revenue by Application (2027-2032)
  9. 11.5 Asia Lung Cancer Screening Software Revenue Share by Application (2021-2032)
  10. 11.6 Asia Lung Cancer Screening Software Revenue by Country
  11. 11.6.1 Asia Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Lung Cancer Screening Software Revenue by Country (2021-2026)
  13. 11.6.3 Asia Lung Cancer Screening Software Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Lung Cancer Screening Software Revenue (2021-2032)
  2. 12.2 SAMEA Lung Cancer Screening Software Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Lung Cancer Screening Software Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Lung Cancer Screening Software Revenue by Type (2027-2032)
  5. 12.3 SAMEA Lung Cancer Screening Software Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Lung Cancer Screening Software Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Lung Cancer Screening Software Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Lung Cancer Screening Software Revenue by Application (2027-2032)
  9. 12.5 SAMEA Lung Cancer Screening Software Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Lung Cancer Screening Software Revenue by Country
  11. 12.6.1 SAMEA Lung Cancer Screening Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Lung Cancer Screening Software Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Lung Cancer Screening Software Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst